Precision BioSciences Says PBGENE-HBV Achieved Undetectable Viral RNA In 100% Of Evaluable Hepatitis B Patients At 0.4 mg/kg In Phase 1; Plans Phase 2 Dosing In Q1 2027

Loading news article.

Precision BioSciences Says PBGENE-HBV Achieved Undetectable Viral RNA In 100% Of Evaluable Hepatitis B Patients At 0.4 mg/kg In Phase 1; Plans Phase 2 Dosing In Q1 2027 | WAPE

Precision BioSciences Says PBGENE-HBV Achieved Undetectable Viral RNA In 100% Of Evaluable Hepatitis B Patients At 0.4 mg/kg In Phase 1; Plans Phase 2 Dosing In Q1 2027

Article summary

Related companies

Analyzed by WAPE AI.

Comments —